Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis
Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).
“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”
GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.
There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5
The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005027/en/
Contact information
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr Julia Faass
Phone: +49 (6132) 77 95614
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com
Additional information
www.boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Peking University Emerges Victorious in 2024 ASC Student Supercomputer Challenge Finals23.4.2024 10:02:00 EEST | Press release
On April 13, 2024, the 2024 ASC Student Supercomputer Challenge (ASC24) Finals drew to a close at Shanghai University after five days of intense competition. Peking University emerged as the undisputed overall champion, securing their place in ASC Student Supercomputer Challenge history. After ASC24 registration opened on November 16, 2023, over 300 teams from universities participated in the intense preliminary contests. As a result, the absolute best 25 teams ascended to the finals hosted at Shanghai University from April 9 to 13, 2024. This marked a groundbreaking moment in ASC history, with the highest number of teams ever qualifying for onsite finals since the competition's inception in 2012. During the finals, teams showcased their skills by designing and building cluster systems capped at a maximum power consumption of 3,000 W. They tackled a lineup of cutting-edge scientific and engineering applications, including HPL and HPCG benchmarks, Large Language Model (LLM), OpenCAEPoro
LatticeFlow AI Joins the U.S. AI Safety Institute Consortium23.4.2024 10:00:00 EEST | Press release
LatticeFlow AI, the leading platform empowering Artificial Intelligence (AI) teams to build performant, safe, and trustworthy AI solutions, proudly announces that it has joined the U.S. AI Safety Institute Consortium (AISIC). LatticeFlow AI researchers will support Working Group #3, focusing on capability evaluations. Together with the National Institute of Standards & Technology (NIST) and other consortium members, LatticeFlow AI will support the development of methods, benchmarks, and testing environments that help organizations operationalize the practices outlined in NIST’s AI Risk Management Framework (RMF). Dave Henry, SVP of Business Development at LatticeFlow AI, added: “AI safety programs are interdisciplinary in nature, requiring a broad range of management and technical skills to execute. The Consortium brings diverse experts together to create durable and innovative practices that promote trustworthy AI. We look forward to contributing our knowledge of AI model safety and c
Manhattan Associates Named a Leader in 2024 Gartner® Magic Quadrant™ for Transportation Management Systems for the Sixth Consecutive Year23.4.2024 10:00:00 EEST | Press release
Manhattan Associates Inc. (NASDAQ: MANH), a global leader in supply chain commerce solutions, announced today that it has been named a Leader in the Gartner Magic Quadrant for Transportation Management Systems for the sixth consecutive year. Manhattan Active® Transportation Management (TM) also ranks among the three highest ranked vendors in the Level 3 Complexity, Level 4 Complexity and Level 5 Complexity Use Cases in the accompanying Critical Capabilities report. As supply chains grow in complexity, enterprises are looking to better orchestrate transportation and distribution processes with a unified supply chain execution solution. Industry experts agree that Manhattan’s cloud-native technology architecture and unified supply chain platform distinguishes Manhattan Active TM. This solution breaks down supply chain execution silos to deliver real-time visibility into shipments, offers predictive analytics for better decision-making, delivers the ability to automate manual processes an
Regula Pinpoints Top Three Business Challenges with Verification of International Customers23.4.2024 10:00:00 EEST | Press release
In addition to the clear risks, such as an increase in fraud, attracting new foreign customers presents less apparent challenges, including the absence of standardized documentation and language barriers. These are the results of a global survey conducted by Regula , a global developer of forensic devices and identity verification solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423489077/en/ Top problems businesses deal with when verifying foreign IDs, according to Regula’s survey (Graphic: Business Wire) Key challenges for businesses When it comes to identity verification for international customers, including a growing community of digital nomads, organizations from various industries participating in Regula’s survey tend to point out the following challenges: The lack of unified document standards. 41% of decision-makers in all sectors report a significant challenge due to the lack of standardized identity do
Antech’s breakthrough cancer screening tool launches in Europe, supporting early canine cancer detection23.4.2024 09:00:00 EEST | Press release
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A rapid, accurate, targeted cancer screening tool for high-risk breeds and older dogs, Nu.Q® testing also includes prevalent types of canine cancers, enabling veterinarians and pet owners to make informed decisions about cancer care more quickly. Jimmy Barr, DVM, DACVECC, Chief Medical Officer at Antech, part of Mars Science & Diagnostics said: “It’s exciting to see innovations like Nu.Q® Canine Cancer Test become more widely available to veterinary teams in Europe. With cancer affecting one in four dogs1, it is critical that veterinary professionals have access to fast and accurate cancer screening methods, so they can make informed and timely decisions and ultimately change pet health outcomes. This is what our work at Antech is all about.” N
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom